Clinical Hypertension最新文献

{"title":"Impact of SGLT2 inhibitors on blood pressure among kidney transplant recipients: insights from a French multicentric cohort (GREAT ASTRE).","authors":"Lucile Baslé, Lucie Maigret, Vincent Dupont, Loïc Lièvre, Nicolas Bouvier, Fabien Duthe, Peggy Perrin, Maïté Jaureguy, Léonard Golbin, Cyril Garrouste, Jean-Philippe Rerolle, Dominique Bertrand, Philippe Rieu, Philippe Gatault, Pierre-Guillaume Deliège","doi":"10.5646/ch.2025.31.e26","DOIUrl":"10.5646/ch.2025.31.e26","url":null,"abstract":"<p><strong>Background: </strong>Blood pressure (BP) control remains a therapeutic challenge in kidney transplant recipients (KTRs). Sodium-glucose cotransporter-2 inhibitors (SGLT2is) lower BP in diabetic and chronic kidney disease patients. Whether this effect extents to KTRs remains to be fully established. We explored the BP lowering potential of SGLT2i, by examining their effects on BP and their influence on antihypertensive drugs prescriptions.</p><p><strong>Methods: </strong>Using the French observational multicenter ASTRE database, we collected systolic BP (SBP), diastolic BP (DBP), weight and drugs, at baseline and at 3 and 6 months after SGLT2i initiation. To evaluate the impact of SGLT2i on other anti-hypertensive drugs management, we used metric such as the defined daily dose (DDD) and the hypertensive index (HTi).</p><p><strong>Results: </strong>Two hundred thirty-four patients were included in the analysis, nearly all had hypertension and 63% had diabetes. By the 3-month mark, there was a significant 4 mmHg reduction in SBP and DBP, which was sustained at 6 months, with decreases of 2.5 mmHg and 3 mmHg (respectively for SBP and DBP). The DDD remained stable. HTi decreased by 14 and 9.5 points at 3 and 6 months, respectively. In multivariate analysis, female sex was associated with a more significant reduction in SBP and HTi.</p><p><strong>Conclusions: </strong>In KTRs newly treated with SGLT2i, BP decreased at 3 and 6 months, while the overall antihypertensive load, as assessed by DDD, remained stable. Similar effects were observed on HTi. These findings suggest SGLT2i as an effective adjunctive therapy for lowering BP in hypertensive KTRs, regardless of diabetes status.</p>","PeriodicalId":10480,"journal":{"name":"Clinical Hypertension","volume":"31 ","pages":"e26"},"PeriodicalIF":3.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145013974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal associations between inflammatory cytokines and hypertensive disorders.","authors":"Xiaosong Li, Zhaoting Gong, Yuejin Yang, Haiyan Qian","doi":"10.5646/ch.2025.31.e27","DOIUrl":"10.5646/ch.2025.31.e27","url":null,"abstract":"<p><strong>Background: </strong>Several inflammatory cytokines (ICs) have been implicated in the development of hypertensive disorders. This study aimed to establish a causal relationship between 91 ICs and hypertensive disorders using Mendelian randomization (MR).</p><p><strong>Methods: </strong>Single nucleotide polymorphisms associated with 91 ICs, hypertension, systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP) were obtained from publicly available genome-wide association studies. MR analyses were conducted using inverse variance weighting as the primary method, complemented by MR-Egger and weighted median approaches. Significant ICs were further analyzed through Gene Ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein-protein interaction (PPI) network analyses.</p><p><strong>Results: </strong>A total of 18 ICs exhibited significant associations with at least 1 hypertensive disorder, with 8, 7, 7, and 5 ICs associated with hypertension, SBP, DBP, and MAP, respectively. Among these, fibroblast growth factor 5 (FGF5) was uniquely associated with all 4 hypertensive conditions. Additionally, FGF5 was identified as a central hub in the PPI network. KEGG pathway analysis highlighted the involvement of the mitogen-activated protein kinase (MAPK) signaling pathway.</p><p><strong>Conclusions: </strong>This study underscores the pivotal role of FGF5 and MAPK signaling pathway in the pathogenesis of hypertensive disorders. Targeting inflammatory pathways may offer therapeutic strategies for hypertension management.</p>","PeriodicalId":10480,"journal":{"name":"Clinical Hypertension","volume":"31 ","pages":"e27"},"PeriodicalIF":3.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12411069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145014036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing systolic blood pressure targets for elderly hypertensive patients: a meta-analysis of mortality, cardiovascular outcomes, and adverse events.","authors":"Sungjoon Park, Ein-Soon Shin, Sang-Hyun Ihm, Hae-Young Lee","doi":"10.5646/ch.2025.31.e25","DOIUrl":"10.5646/ch.2025.31.e25","url":null,"abstract":"<p><strong>Background: </strong>Hypertension is a common health issue among elderly populations, substantially increasing morbidity and mortality risks. This meta-analysis aimed to determine optimal systolic blood pressure (SBP) targets in elderly hypertensive patients and their effects on clinical outcomes.</p><p><strong>Methods: </strong>We conducted a systematic search of PubMed, Embase, and the Cochrane Library to identify randomized controlled trials involving antihypertensive therapy in participants aged 60 years and older. Mortality, cardiovascular events, and significant adverse events data were extracted and analyzed using random-effects models.</p><p><strong>Results: </strong>The analysis included 24 studies, with 9 specifically examining elderly participants aged 60 and older. Targeting a lower SBP of less than 140 mmHg was associated with significant reductions in primary outcome events (relative risk [RR], 0.69; 95% confidence interval [CI], 0.56-0.86), all-cause mortality (RR, 0.64; 95% CI, 0.49-0.83), cardiovascular mortality (RR, 0.59; 95% CI, 0.39-0.87), and stroke (RR, 0.68; 95% CI, 0.47-0.98; I² = 0%). Achieving an intensive SBP target in the pooled range less than 130 mmHg reduced the risks of primary outcome events (RR, 0.73; 95% CI, 0.62-0.85), heart failure (RR, 0.57; 95% CI, 0.38-0.84), and stroke (RR, 0.72; 95% CI, 0.53-0.96), though it also led to an elevated risk of hypotension (RR, 1.43; 95% CI, 1.18-1.73).</p><p><strong>Conclusions: </strong>In elderly hypertensive patients, lower SBP targets correlate with improved clinical outcomes, including reduced mortality and cardiovascular events. Nonetheless, the heightened risk of adverse effects underscores the need for careful, individualized treatment strategies. Additional research is warranted to refine these targets and achieve a balance between therapeutic efficacy and safety.</p>","PeriodicalId":10480,"journal":{"name":"Clinical Hypertension","volume":"31 ","pages":"e25"},"PeriodicalIF":3.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12322049/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144788350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Posttreatment pulse rate reduction and not baseline pulse rate as an indicator of blood pressure response to nebivolol: a subanalysis from the real-world BENEFIT-KOREA study.","authors":"Jinho Shin, Dong Hoon Cha, Woo-Hyung Bae, In Hyun Jung, Seung-Pyo Hong, Sang-Hyun Kim, Jun-Young Do, Won Min Hwang, Young Youp Koh, Giuseppe Mancia, Athanasios J Manolis, MinYoung Lee","doi":"10.5646/ch.2025.31.e24","DOIUrl":"10.5646/ch.2025.31.e24","url":null,"abstract":"<p><p>[This corrects the article e8 in vol. 31, PMID: 40083595.].</p>","PeriodicalId":10480,"journal":{"name":"Clinical Hypertension","volume":"31 ","pages":"e24"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: The role of ambulatory blood pressure monitoring in enhancing medication adherence among patients with newly diagnosed hypertension: an analysis of the National Health Insurance cohort database.","authors":"Hack-Lyoung Kim, So-Jeong Park, Yoon-Jong Bae, Sang Hyun Ihm, Jinho Shin, Kwang-Il Kim","doi":"10.5646/ch.2025.31.e23","DOIUrl":"10.5646/ch.2025.31.e23","url":null,"abstract":"<p><p>[This corrects the article 6 in vol. 30, PMID: 38424656.].</p>","PeriodicalId":10480,"journal":{"name":"Clinical Hypertension","volume":"31 ","pages":"e23"},"PeriodicalIF":2.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12230166/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of watch-based blood pressure monitoring device in daily blood pressure monitoring.","authors":"Youngro Lee, Sungjoon Park, Jongae Park, Jongmo Seo, Hae-Young Lee","doi":"10.5646/ch.2025.31.e21","DOIUrl":"10.5646/ch.2025.31.e21","url":null,"abstract":"<p><strong>Background: </strong>Cuffless blood pressure (BP) measurement devices integrated into smartwatches have gained prominence, yet limited studies provide the feasibility and preciseness of daily BP monitoring. Here, we evaluated the trackability of daily BP variance and the precision of the calibration process.</p><p><strong>Methods: </strong>We collected the data from 896 participants, reporting 35,592 BP values, and body composition analysis data measured by the Samsung Galaxy Watch 6 device. Participants were instructed to measure BP daily, in the morning (5 AM-9 AM) and evening (6 PM-10 PM) for 2 weeks, with initial calibration and re-calibration after the first week. Body composition data, obtained using the Galaxy Watch's bioelectrical impedance analysis sensor, was measured voluntarily during the campaign without specific time constraints.</p><p><strong>Results: </strong>With BP readings collected using smartwatches, morning and evening BP values showed a significant difference, higher in the evening by 1.42 ± 5.25 mmHg (<i>P</i> < 0.05). Basal metabolic rate, skeletal muscle mass, total body water, morning systolic BP, morning pulse pressure, and morning heart rate were significantly associated with higher difference in morning-evening BP. The calibration stability was assessed by the difference in average BP before and after calibration, showing a substantial pre-post calibration BP difference by 4.64 ± 4.73 mmHg of systolic BP and 3.66 ± 3.62 mmHg of diastolic BP.</p><p><strong>Conclusions: </strong>In conclusion, watch-based devices may not detect clinical-level BP variability, and substantial extent of pre-post calibration error has to be solved for their utility in regular real-life BP monitoring.</p>","PeriodicalId":10480,"journal":{"name":"Clinical Hypertension","volume":"31 ","pages":"e21"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145889/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of renin-angiotensin system inhibitors on colorectal neoplasm development.","authors":"Yoo Min Han, Ji Min Choi, Tae-Min Rhee, Su-Yeon Choi, Heesun Lee","doi":"10.5646/ch.2025.31.e22","DOIUrl":"10.5646/ch.2025.31.e22","url":null,"abstract":"<p><strong>Background: </strong>Renin-angiotensin system (RAS) inhibitors have shown potential chemopreventive effects against colorectal cancer (CRC). However, little is known about the impact of RAS inhibitors on the risk of colorectal precancerous lesions.</p><p><strong>Methods: </strong>Preclinically, we established mouse models of colitis-associated colon cancer and xenografts: vehicle, 1 mg/kg, 5 mg/kg enalapril groups. Body weight, colon length, and colorectal tumor size were evaluated on the euthanization day. Clinically, we retrospectively recruited 8,388 asymptomatic adults undergoing their first-ever colonoscopy for health check-ups (index cohort). From the index cohort, we selected individuals undergoing follow-up colonoscopy (follow-up cohort). The study outcome was incidental and recurrent colorectal neoplasms, including CRC. We evaluated the prevalence and risk of colorectal neoplasms associated with RAS inhibitor use of ≥ 1 year.</p><p><strong>Results: </strong>In the experimental study, enalapril administration significantly attenuated weight loss and colon shortening, reduced tumor numbers in colitis-associated colon cancer models, and decreased tumor volume in the xenografts. In the index cohort, while the initial analysis showed a positive association with the RAS inhibitor use (unadjusted odds ratio [OR], 1.22), this shifted toward an inverse trend after adjusting for confounders (adjusted OR, 0.91). During follow-up (median, 41.0 months), incidental and recurrent colorectal neoplasms were less common in the RAS inhibitor group (32.6%) than in the other anti-hypertensives group (39.1%) (<i>P</i> < 0.001), despite similar intervals between the index and follow-up endoscopies. In the follow-up cohort, hypertension itself was a risk factor for colorectal neoplasm development (adjusted hazard ratio [HR], 1.70; 95% confidence interval [CI], 1.00-2.53; <i>P</i> = 0.049), whereas RAS inhibitor use was significantly associated with a 27% lower risk (adjusted HR, 0.73; 95% CI, 0.59-0.95; <i>P</i> = 0.035).</p><p><strong>Conclusions: </strong>Long-term, regular use of RAS inhibitors independently reduces the risk of colorectal neoplasms, irrespective of dosage or drug type. Given their potential chemopreventive effects on colorectal neoplasms, RAS inhibitors may serve as a preventive strategy starting from the precancerous stage.</p>","PeriodicalId":10480,"journal":{"name":"Clinical Hypertension","volume":"31 ","pages":"e22"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12145888/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lowering of systolic blood pressure with ESPRIT along the BPROAD: the lower the better?","authors":"Reinhold Kreutz, Mattias Brunström","doi":"10.5646/ch.2025.31.e20","DOIUrl":"https://doi.org/10.5646/ch.2025.31.e20","url":null,"abstract":"<p><p>Recent studies have renewed the debate over optimal systolic blood pressure (SBP) targets in hypertensive patients, particularly those at increased cardiovascular (CV) risk and with type 2 diabetes mellitus (T2DM). The Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events (ESPRIT) and Blood Pressure Control Target in Diabetes (BPROAD) randomized controlled trials, both conducted in Chinese populations, offer new insights into intensive versus standard SBP-lowering strategies. ESPRIT enrolled 11,255 patients with high CV risk (including 38.7% with T2DM), while BPROAD included 12,821 hypertensive patients with T2DM and elevated CV risk. Both trials compared intensive SBP lowering (< 120 mmHg) with standard treatment (< 140 mmHg). Results from both studies showed that intensive treatment significantly reduced the incidence of major adverse cardiovascular events (MACE). ESPRIT reported a hazard ratio (HR) of 0.88 for MACE, along with notable reductions in CV and all-cause mortality. BPROAD similarly found a HR of 0.79 for MACE, although it did not demonstrate a statistically significant benefit in all-cause mortality. However, intensive treatment in both trials was associated with higher-though relatively low-absolute rates of adverse events, including hypotension, syncope, and renal impairment. When considered alongside previous trials, our meta-analysis suggests a consistent reduction in MACE risk with intensive SBP control. Nevertheless, concerns remain regarding the safety profile and generalizability of these findings, particularly given that both ESPRIT and BPROAD were limited to ethnically Chinese cohorts and reported unusually low adverse event rates compared to Western studies. In summary, the cumulative evidence suggests that an SBP target < 140 mmHg may be suboptimal. However, whether a target < 120 mmHg is superior to the current guideline-recommended range of 120-129 mmHg remains uncertain. No trials have directly compared < 120 mmHg with < 130 mmHg. Therefore, future research should determine whether the additional benefits of more aggressive SBP lowering outweigh potential risks, especially in diverse populations with and without diabetes.</p>","PeriodicalId":10480,"journal":{"name":"Clinical Hypertension","volume":"31 ","pages":"e20"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of meal replacements therapy on blood pressure and C-reactive protein: a systematic review and meta-analysis of randomized controlled trials.","authors":"Danial Fotros, Pejman Rohani, Kousalya Prabahar, Somaye Fatahi, Mohammad Hassan Sohouli, Nathalia Sernizon Guimarães","doi":"10.5646/ch.2025.31.e17","DOIUrl":"https://doi.org/10.5646/ch.2025.31.e17","url":null,"abstract":"<p><p>Although some evidence shows the beneficial effects of meal replacement (MR) on blood pressure (BP) and inflammation as one of the main factors of cardiovascular disease, there are still no comprehensive findings in this field. Therefore, we investigate the effects of total and partial MRs on BP and C-reactive protein (CRP) in this comprehensive study and meta-analysis. In order to identify all randomized controlled trials that investigated the effects of MRs on BP and CRP levels, a systematic search was conducted in the original databases using predefined keywords. The pooled weighted mean difference (WMD) and 95% confidence intervals (CIs) were computed using the random-effects model. Forty studies were included in this article. The findings indicated significant reductions in systolic blood pressure (SBP) (WMD, -2.51 mmHg; 95% CI, -3.48 to -1.54; <i>P</i> < 0.001), diastolic blood pressure (DBP) (WMD, -1.43 mmHg; 95% CI, -2.02 to -0.85; <i>P</i> < 0.001), and CRP (WMD, -0.50 mg/L; 95% CI, -0.89 to -0.11; <i>P</i> = 0.012) levels following MR consumption compared to the control group. The findings obtained from the subgroup analysis showed that MRs cause a greater reduction in SBP in people over 50 years of age, and the duration of the intervention ≤ 24 weeks. Also, the subgroup analysis shows the greater effect of DBP and CRP, respectively, in the type of intervention with total meal replacement and less equal to 50 years. In conclusion, it appears that MR, along with other lifestyle factors, can lead to significant improvements in BP and CRP.</p>","PeriodicalId":10480,"journal":{"name":"Clinical Hypertension","volume":"31 ","pages":"e17"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors associated with medication adherence among young adults with hypertension.","authors":"Eunji Kim, Hyeok-Hee Lee, Eun-Jin Kim, So Mi Jemma Cho, Hyeon Chang Kim, Hokyou Lee","doi":"10.5646/ch.2025.31.e18","DOIUrl":"https://doi.org/10.5646/ch.2025.31.e18","url":null,"abstract":"<p><strong>Background: </strong>Poor adherence to antihypertensive medication remains a significant barrier to blood pressure control in young patients. The objective of this study was to identify factors associated with antihypertensive medication adherence among young adults with hypertension.</p><p><strong>Methods: </strong>From the Korean National Health Insurance Service database, we included 141,132 participants aged 20 to 39 years (80.4% male), without cardiovascular disease, who initiated antihypertensive medication between 2013 and 2018. Participants were categorized as exhibiting good adherence (proportion of days covered [PDC] ≥ 0.8) or poor adherence (PDC < 0.8) to antihypertensive medication during the first year of treatment. We investigated the associations of demographic, lifestyle, and clinical factors with good medication adherence based on logistic regression analysis.</p><p><strong>Results: </strong>Only 43.3% (<i>n</i> = 61,107) of young adults with hypertension showed good adherence to antihypertensive medication. Male sex, older age, higher income, urban residence, non-smoking, and higher physical activity were associated with good medication adherence. Initial combination therapy, especially with single-pill combination (odds ratio [OR], 1.12; 95% confidence interval [CI], 1.07-1.18), was associated with good adherence. Among patients under monotherapy, initial use of renin-angiotensin blockers (OR, 5.24; 95% CI, 4.47-6.15) or calcium-channel blockers (OR, 4.07; 95% CI, 3.47-4.78) was associated with better adherence than initial diuretics.</p><p><strong>Conclusions: </strong>Although antihypertensive medication adherence is generally poor among young adults, we identified potential demographic and clinical factors associated with good adherence to antihypertensive treatment. Initial use of a single-pill combination may promote adherence in young patients, and its long-term clinical outcomes warrant further investigation.</p>","PeriodicalId":10480,"journal":{"name":"Clinical Hypertension","volume":"31 ","pages":"e18"},"PeriodicalIF":2.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12055495/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}